NORTHERN NEW JERSEY COMMUNITY CLINICAL ONCOLOGY PROGRAM

新泽西州北部社区临床肿瘤学计划

• 批准号: 2088825
• 负责人: RICHARD J ROSENBLUTH
• 金额: $ 26.53万
• 依托单位: HACKENSACK UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1983
• 资助国家: 美国
• 起止时间: 1983-09-01 至 1997-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2088825
• 关键词: antineoplastics; cancer information system; cancer prevention; cancer registry /resource; cancer rehabilitation /care; cervical /vaginal smear; clinical trials; community health services; continuing education; cooperative study; drug screening /evaluation; early diagnosis; human subject; human therapy evaluation; neoplasm /cancer education; neoplasm /cancer therapy; patient /disease registry; pediatric neoplasm /cancer; pharmacy administration; primary care physician; prostate neoplasms

The Northern New Jersey Community Clinical Oncology Program (NNJ-CCOP) provides access to national cooperative clinical trials for over 4.9 million people in the 9 most populous counties in northern New Jersey and bordering New York. Against this background, the Hackensack Medical Center (HMC) diagnoses 1500 new cancer patients per year, an increase of 30% in the last five years. Patient volumes have increased markedly in both Adult and Pediatric Oncology. Increased volume together with the growth and expansion of the oncology facilities and programs at the Medical Center form a perfect backdrop for increased research contributions during the next 5 years. The NNJ-CCOP brings together the strength and resources of a group of multidisciplinary investigators who collaborate in the conduct of studies from POG, ECOG, NSABP, and URCC. The investigators number 29 including 13 hematologists/oncologists in two hospital-based private practice groups serving patients of all ages. Their accomplishments are superior in both the science of the research as well as accrual to clinical trials. Over the next five years, the overall aim is to reduce cancer incidence, morbidity, and mortality by accelerating the transfer of newly developed cancer prevention, early detection, treatment, patient management, rehabilitation, and continuing care technology to widespread community application. By careful design, the program will focus as much, if not more, attention and resources on cancer control research than treatment These twin objectives of both treatment and cancer control are a ready match for the patient population and fit within NNJ-CCOP interests and capabilities. The immediate goals of the NNJ-CCOP are to continue our strong accrual rate to treatment trials; to increase research activity by offering additional studies on our treatment protocol menu; to facilitate wider community participation, including minority groups and underserved populations in treatment and cancer control research approved by NCl; to cultivate contacts with primary care physicians and other specialists who may contribute to cancer control initiatives; and to refine cancer control data management capabilities, including the use of a range of resources to identify potential candidates for cancer control research projects. The conduct of the Prostate Cancer Prevention Trial (PCPT) is a primary objective. For this study, the CCOP is 1 of 2 approved Study Centers in New Jersey. In summary, the track record of the NNJ-CCOP demonstrates the ability to manage complex clinical research and cancer control activities while producing the highest quality data. The NNJ-CCOP has the facilities and well-trained professional personnel to support both cancer treatment and cancer control trials. The CCOP staffing pattern, protocol management procedures, patient / participant management approaches, quality control mechanisms, pharmacy control mechanisms, IRB structure and liaison are all in place and functioning to support current and future therapeutic and cancer control activities. Between 1994 and 1999, over 2200 protocol entries will be contributed to CCOP clinical trials: 665 entries to treatment trials and 1560 entries to cancer control trials per year for 153.5 treatment credits and 131.5 cancer control credits.

新泽西州北部社区临床肿瘤学计划 (NNJ-CCOP) 提供超过 4.9 的国家合作临床试验机会 新泽西州北部人口最多的 9 个县和 与纽约接壤。在此背景下，哈肯萨克医学中心 (HMC) 每年诊断出 1500 名新癌症患者，增加了 30% 过去五年。成人患者数量显着增加 和小儿肿瘤学。数量随着增长而增加 扩大医疗中心的肿瘤设施和项目 为在此期间增加研究贡献奠定了完美的背景 未来5年。 NNJ-CCOP 汇集了一组的力量和资源 合作进行研究的多学科研究人员 来自 POG、ECOG、NSA​​BP 和 URCC。调查人员29人，其中13人 两个医院私人诊所的血液科医生/肿瘤科医生 服务于各个年龄段的患者。他们的成就在这两方面都更胜一筹 研究的科学性以及临床试验的收益。 未来五年的总体目标是降低癌症发病率 通过加速新开发的技术的转移来降低发病率和死亡率 癌症预防、早期发现、治疗、患者管理、 向广大社区提供康复和持续护理技术 应用。通过精心设计，该程序将尽可能集中精力，即使不是 癌症控制研究比治疗受到更多关注和资源 治疗和癌症控制的这两个双重目标是现成的 与患者群体相匹配并符合 NNJ-CCOP 的兴趣， 能力。 NNJ-CCOP 的近期目标是继续我们强大的应计收益 治疗试验率；通过提供来增加研究活动 关于我们的治疗方案菜单的其他研究；以方便更广泛的 社区参与，包括少数群体和服务不足的群体 NCl 批准的治疗和癌症控制研究人群；到 与初级保健医生和其他专家建立联系 可能有助于癌症控制举措；并完善癌症控制 数据管理能力，包括使用一系列资源 确定癌症控制研究项目的潜在候选人。这 进行前列腺癌预防试验 (PCPT) 是一项主要措施 客观的。对于本研究，CCOP 是 2 个经批准的研究中心之一 新泽西州。 总之，NNJ-CCOP 的跟踪记录表明有能力 管理复杂的临床研究和癌症控制活动，同时 产生最高质量的数据。 NNJ-CCOP 拥有设施和 训练有素的专业人员支持癌症治疗和 癌症控制试验。 CCOP 人员配置模式、协议管理 程序、患者/参与者管理方法、质量控制 机制、药房控制机制、IRB 结构和联络都是 到位并发挥作用，以支持当前和未来的治疗和 癌症控制活动。 1994 年至 1999 年间，将贡献超过 2200 个协议条目 CCOP 临床试验：665 项治疗试验和 1560 项治疗试验 每年癌症控制试验 153.5 个治疗学分和 131.5 个治疗学分 癌症控制学分。